Rx0000106 |
Neos Therapeutics, Inc. |
12/31/2022 |
70165002030 |
ADZENYS XR-ODT 12.5MG, 30 CT Tablets |
10/01/2022 |
21.78 |
457.38 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000106 |
Neos Therapeutics, Inc. |
12/31/2022 |
70165002530 |
ADZENYS XR-ODT 15.7MG, 30 CT Tablets |
10/01/2022 |
21.78 |
457.38 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000106 |
Neos Therapeutics, Inc. |
12/31/2022 |
70165003030 |
ADZENYS XR-ODT 18.8MG, 30 CT Tablets |
10/01/2022 |
21.78 |
457.38 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000106 |
Neos Therapeutics, Inc. |
12/31/2022 |
70165000530 |
ADZENYS XR-ODT 3.1MG, 30 CT Tablets |
10/01/2022 |
21.78 |
457.38 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000106 |
Neos Therapeutics, Inc. |
12/31/2022 |
70165001030 |
ADZENYS XR-ODT 6.3MG, 30 CT Tablets |
10/01/2022 |
21.78 |
457.38 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000106 |
Neos Therapeutics, Inc. |
12/31/2022 |
70165001530 |
ADZENYS XR-ODT 9.4MG, 30 CT Tablets |
10/01/2022 |
21.78 |
457.38 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000106 |
Neos Therapeutics, Inc. |
12/31/2022 |
70165020030 |
COTEMPLA XR-ODT 17.3MG, 30 CT Tablets |
10/01/2022 |
22.26 |
467.46 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000106 |
Neos Therapeutics, Inc. |
12/31/2022 |
70165030030 |
COTEMPLA XR-ODT 25.9MG, 30 CT Tablets |
10/01/2022 |
22.26 |
467.46 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000106 |
Neos Therapeutics, Inc. |
12/31/2022 |
70165010030 |
COTEMPLA XR-ODT 8.6MG, 30 CT Tablets |
10/01/2022 |
22.26 |
467.46 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000366 |
Neurocrine Biosciences, Inc. |
12/31/2022 |
70370204001 |
INGREZZA ORAL CAPSULE 40 MG, BOTTLE OF 30 CAPSULES |
10/20/2022 |
603.00 |
7302.00 |
08/10/2040 |
Single Source Drug |
None |
1 |
Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles:
-Improving the lives and well-being of patients
-Maximizing access and reducing out-of-pocket costs for eligible patients
-Striving to reduce obstacles for patients to fill a prescription or undergo treatment
-Fueling the discovery and development of life-changing medicines |
None |
The price increase was not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000366 |
Neurocrine Biosciences, Inc. |
12/31/2022 |
70370108001 |
INGREZZA ORAL CAPSULE 80 MG, BOTTLE OF 30 CAPSULES |
10/20/2022 |
662.00 |
8022.00 |
08/10/2040 |
Single Source Drug |
None |
1 |
Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles:
-Improving the lives and well-being of patients
-Maximizing access and reducing out-of-pocket costs for eligible patients
-Striving to reduce obstacles for patients to fill a prescription or undergo treatment
-Fueling the discovery and development of life-changing medicines |
None |
The price increase was not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000366 |
Neurocrine Biosciences, Inc. |
12/31/2022 |
70370204806 |
INGREZZA ORAL CAPSULE INITIATION PACK 40 MG (7) AND 80 MG (21), BLISTER PACK OF 28 CAPSULES |
10/20/2022 |
662.00 |
8022.00 |
08/10/2040 |
Single Source Drug |
None |
1 |
Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles:
-Improving the lives and well-being of patients
-Maximizing access and reducing out-of-pocket costs for eligible patients
-Striving to reduce obstacles for patients to fill a prescription or undergo treatment
-Fueling the discovery and development of life-changing medicines |
None |
The price increase was not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000364 |
NextWave Pharmaceuticals, Inc. |
03/31/2022 |
24478032102 |
QUILLIVANT XR 300mg in 60mL Powder 1 60mL Bottle 1 Carton |
01/03/2022 |
9.98 |
338.93 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000364 |
NextWave Pharmaceuticals, Inc. |
03/31/2022 |
24478032204 |
QUILLIVANT XR 600mg in 120mL Powder 1 120mL Bottle 1 Carton |
01/03/2022 |
9.98 |
338.93 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000364 |
NextWave Pharmaceuticals, Inc. |
03/31/2022 |
24478032305 |
QUILLIVANT XR 900mg in 180mL Powder 1 180mL Bottle 1 Carton |
01/03/2022 |
9.98 |
338.93 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000364 |
NextWave Pharmaceuticals, Inc. |
03/31/2022 |
24478032406 |
QUILLIVANT XR750mg in 150mL Powder 1 150mL Bottle 1 Carton |
01/03/2022 |
9.98 |
338.93 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000418 |
Nexus Pharmaceuticals, Inc. |
09/30/2022 |
14789090110 |
Procainamide HCL 100 mg 10mL Vial Pack of 10 |
09/07/2022 |
3000.00 |
6000.00 |
None |
Non-innovator Multiple Source Drug |
6790 |
None |
Nexus considers multiple factors in determining ongoing pricing of their prescription drugs including value provided to patients, patient populations and changing market and competitive conditions. |
None |
no change |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000418 |
Nexus Pharmaceuticals, Inc. |
09/30/2022 |
14789090002 |
Procainamide HCL 500mg 2mL Vial Pack of 10 |
09/07/2022 |
3000.00 |
6000.00 |
None |
Non-innovator Multiple Source Drug |
15140 |
None |
Nexus considers multiple factors in determining ongoing pricing of their prescription drugs including value provided to patients, patient populations and changing market and competitive conditions. |
None |
no change |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000420 |
Nielsen BioSciences, Inc. |
12/31/2022 |
59584013801 |
Candin skin test antigen 1 U/.1mL 1mL vial liquid |
10/10/2022 |
29.00 |
272.00 |
None |
Single Source Drug |
31873 |
None |
When pricing its products, Nielsen takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000420 |
Nielsen BioSciences, Inc. |
12/31/2022 |
59584014001 |
Spherusol skin test antigen 12.7 ug/mL 1mL vial liquid |
10/10/2022 |
138.00 |
1056.00 |
None |
Single Source Drug |
1155 |
None |
When pricing its products, Nielsen takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000204 |
Noden Pharma USA, Inc. |
03/31/2022 |
70839015030 |
TEKTURNA 150MG TAB 30/EA |
01/01/2022 |
22.02 |
266.64 |
08/19/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000204 |
Noden Pharma USA, Inc. |
03/31/2022 |
70839030030 |
TEKTURNA 300MG TAB 30/EA |
01/01/2022 |
27.78 |
336.39 |
08/19/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000204 |
Noden Pharma USA, Inc. |
03/31/2022 |
70839031230 |
TEKTURNA HCT 300/12.5MG TAB 30/EA |
01/01/2022 |
27.78 |
336.39 |
07/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000204 |
Noden Pharma USA, Inc. |
03/31/2022 |
70839032530 |
TEKTURNA HCT 300/25MG TAB 30/EA |
01/01/2022 |
27.78 |
336.39 |
07/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000073 |
Novartis |
09/30/2022 |
00065027510 |
AZOPT® 1% 10 mL DT |
07/27/2022 |
17.16 |
360.39 |
07/02/2017 |
Innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00065027515 |
AZOPT® 1% 15 mL DT |
07/27/2022 |
25.74 |
540.54 |
07/02/2017 |
Innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078063968 |
Cosentyx 150mg/ml, pen, 1 Sensoready Pen |
01/05/2022 |
415.05 |
6344.38 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078063968 |
Cosentyx 150mg/ml, pen, 1 Sensoready Pen |
07/27/2022 |
126.89 |
6471.27 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078063941 |
Cosentyx 150mg/ml, pen, 2 Sensoready Pens |
01/05/2022 |
415.05 |
6344.38 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078063941 |
Cosentyx 150mg/ml, pen, 2 Sensoready Pens |
07/27/2022 |
126.89 |
6471.27 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078063997 |
Cosentyx 150mg/ml, syringe, 1 Syringe |
01/05/2022 |
415.05 |
6344.38 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078063997 |
Cosentyx 150mg/ml, syringe, 1 Syringe |
07/27/2022 |
126.89 |
6471.27 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078063998 |
Cosentyx 150mg/ml, syringe, 2 Syringes |
01/05/2022 |
415.05 |
6344.38 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078063998 |
Cosentyx 150mg/ml, syringe, 2 Syringes |
07/27/2022 |
126.89 |
6471.27 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00065924007 |
DUREZOL® 0.05% 5 mL DT |
07/27/2022 |
10.38 |
218.00 |
11/18/2019 |
Innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078065967 |
Entresto 24/26mg - Tabs, 180 Each Bottle, 1 bottle |
01/05/2022 |
122.41 |
1871.09 |
05/09/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078065967 |
Entresto 24/26mg - Tabs, 180 Each Bottle, 1 bottle |
07/27/2022 |
37.42 |
1908.51 |
05/09/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078065920 |
Entresto 24/26mg - Tabs, 60 Each Bottle, 1 bottle |
01/05/2022 |
40.80 |
623.69 |
05/09/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078065920 |
Entresto 24/26mg - Tabs, 60 Each Bottle, 1 bottle |
07/27/2022 |
12.47 |
636.16 |
05/09/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078077767 |
Entresto 49/51mg - Tabs, 180 Each Bottle, 1 bottle |
01/05/2022 |
122.41 |
1871.09 |
05/09/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078077767 |
Entresto 49/51mg - Tabs, 180 Each Bottle, 1 bottle |
07/27/2022 |
37.42 |
1908.51 |
05/09/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078077720 |
Entresto 49/51mg - Tabs, 60 Each Bottle, 1 bottle |
01/05/2022 |
40.80 |
623.69 |
08/22/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078069667 |
Entresto 97/103mg - Tabs, 180 Each Bottle, 1 bottle |
01/05/2022 |
122.41 |
1871.09 |
05/09/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078069667 |
Entresto 97/103mg - Tabs, 180 Each Bottle, 1 bottle |
07/27/2022 |
37.42 |
1908.51 |
05/09/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078069620 |
Entresto 97/103mg - Tabs, 60 Each Bottle, 1 bottle |
01/05/2022 |
40.80 |
623.69 |
08/22/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078077720 |
ENTRESTO® tablets 49mg/51mg 60s |
07/27/2022 |
12.47 |
636.16 |
05/09/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078069620 |
ENTRESTO® tablets 97mg/103mg 60s |
07/27/2022 |
12.47 |
636.16 |
05/09/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078060715 |
GILENYA capsules 0.5mg 30s |
01/05/2022 |
454.77 |
9550.11 |
12/25/2027 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078060715 |
GILENYA capsules 0.5mg 30s |
07/27/2022 |
191.00 |
9741.11 |
12/25/2027 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078074303 |
ILEVRO® 0.3% 3 mL |
07/27/2022 |
6.46 |
329.47 |
03/31/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078086001 |
KISQALI 200mg daily dose, 1 blister pack x 21 tablets (21 tablets per carton) |
01/05/2022 |
396.77 |
6064.92 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078086742 |
KISQALI 400mg daily dose, 3 blister packs x 14 tablets (42 tablets per carton) |
01/05/2022 |
793.54 |
12129.88 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078087463 |
KISQALI 600mg daily dose, 3 blister packs x 21 tablets (63 tablets per carton) |
01/05/2022 |
991.93 |
15162.35 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078090961 |
KISQALI FEMARA CO-PACK, Kisqali 1 blister pack, containing 21 tablets 200mg per tablet, Femara 2.5mg 28s |
01/05/2022 |
396.77 |
6064.92 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078091661 |
KISQALI FEMARA CO-PACK, Kisqali 3 blister packs, containing 14 tablets (200mg per tablet) (400mg daily |
01/05/2022 |
793.54 |
12129.88 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078092361 |
KISQALI FEMARA CO-PACK, Kisqali 3 blister packs, containing 21 tablets (200mg per tablet) (600mg daily dose), Femara 2.5mg 28s |
01/05/2022 |
991.93 |
15162.35 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078097950 |
MAYZENT tablets .25mg 28s |
01/05/2022 |
94.01 |
1974.15 |
11/30/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078097950 |
MAYZENT tablets .25mg 28s |
07/27/2022 |
39.48 |
2013.63 |
11/30/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078098615 |
MAYZENT tablets 2mg 30s |
01/05/2022 |
402.89 |
8460.63 |
11/30/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078098615 |
MAYZENT tablets 2mg 30s |
07/27/2022 |
169.21 |
8629.84 |
11/30/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078066615 |
Mekinist 0.5 mg 30 tabs per bottle, 1 bottle |
01/05/2022 |
203.63 |
3905.92 |
08/30/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00078066615 |
Mekinist 0.5 mg 30 tabs per bottle, 1 bottle |
07/27/2022 |
78.12 |
3984.04 |
08/30/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078066815 |
Mekinist 2 mg 30 tabs per bottle, 1 bottle |
01/05/2022 |
693.04 |
13293.83 |
08/30/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00078066815 |
Mekinist 2 mg 30 tabs per bottle, 1 bottle |
07/27/2022 |
265.88 |
13559.71 |
08/30/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078070184 |
PIQRAY tablets 200mg 28s |
01/05/2022 |
1224.80 |
18721.98 |
09/28/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078071502 |
PIQRAY tablets 250mg 56s |
01/05/2022 |
1224.80 |
18721.98 |
09/28/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078070802 |
PIQRAY tablets 300mg 56s |
01/05/2022 |
1224.80 |
18721.98 |
09/28/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078068415 |
Promacta 12.5 mg, 30 tabs per bottle, 1 bottle |
01/05/2022 |
394.82 |
6035.13 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00078068415 |
Promacta 12.5 mg, 30 tabs per bottle, 1 bottle |
07/27/2022 |
120.70 |
6155.83 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078068515 |
Promacta 25 mg, 30 tabs per bottle, 1 bottle |
01/05/2022 |
394.82 |
6035.13 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00078068515 |
Promacta 25 mg, 30 tabs per bottle, 1 bottle |
07/27/2022 |
120.70 |
6155.83 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078068615 |
Promacta 50 mg, 30 tabs per bottle, 1 bottle |
01/05/2022 |
714.50 |
10921.67 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00078068615 |
Promacta 50 mg, 30 tabs per bottle, 1 bottle |
07/27/2022 |
218.43 |
11140.10 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078068715 |
Promacta 75 mg, 30 tabs per bottle, 1 bottle |
01/05/2022 |
1071.75 |
16382.51 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00078068715 |
Promacta 75 mg, 30 tabs per bottle, 1 bottle |
07/27/2022 |
327.65 |
16710.16 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078097261 |
PROMACTA powder for oral suspension 12.5mg 30s Kit |
01/05/2022 |
394.82 |
6035.13 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00078097261 |
PROMACTA powder for oral suspension 12.5mg 30s Kit |
07/27/2022 |
120.70 |
6155.83 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00078069761 |
PROMACTA® powder for oral suspension 12.5mg 30s Kit |
07/27/2022 |
120.71 |
6156.16 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00078068655 |
PROMACTA® tablets 50mg 14s |
07/27/2022 |
101.94 |
5198.71 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078069819 |
Rydapt 25 mg, 112 tabs per bottle, 1 bottle |
01/05/2022 |
1040.78 |
19964.05 |
12/02/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078069899 |
Rydapt 25 mg, 56 tabs per bottle, 1 bottle |
01/05/2022 |
520.39 |
9982.03 |
12/02/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078068266 |
Tafinlar 50 mg, 120 tabs per bottle, 1 bottle |
01/05/2022 |
495.30 |
9500.83 |
08/30/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00078068266 |
Tafinlar 50 mg, 120 tabs per bottle, 1 bottle |
07/27/2022 |
190.02 |
9690.85 |
08/30/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078068166 |
Tafinlar 75 mg, 120 tabs per bottle, 1 bottle |
01/05/2022 |
638.32 |
12244.20 |
08/30/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
09/30/2022 |
00078068166 |
Tafinlar 75 mg, 120 tabs per bottle, 1 bottle |
07/27/2022 |
244.88 |
12489.08 |
08/30/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000073 |
Novartis |
03/31/2022 |
00078059287 |
Tasigna 150mg, 28 capsule per bottle, 4 bottles |
01/05/2022 |
944.77 |
16690.91 |
10/07/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078059287 |
Tasigna 150mg, 28 capsule per bottle, 4 bottles |
07/27/2022 |
333.82 |
17024.73 |
10/07/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078052687 |
Tasigna 200mg, 28 capsule per bottle, 4 bottles |
01/05/2022 |
944.77 |
16690.91 |
10/07/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078052687 |
Tasigna 200mg, 28 capsule per bottle, 4 bottles |
07/27/2022 |
333.82 |
17024.73 |
10/07/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078095166 |
Tasigna 50mg, 120 capsule per bottle, 1 bottle |
01/05/2022 |
1012.25 |
17883.06 |
10/07/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
09/30/2022 |
00078095166 |
Tasigna 50mg, 120 capsule per bottle, 1 bottle |
07/27/2022 |
357.66 |
18240.72 |
10/07/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2022 |
00078067066 |
Votrient 200 mg 120 tabs per bottle, 1 bottle |
01/05/2022 |
800.62 |
15357.34 |
10/19/2023 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2022 |
68968051408 |
CombiPatch Transdermal Patch Twice Weekly 0.05-0.14 MG/DAY - 8 each |
01/01/2022 |
11.02 |
231.49 |
None |
Single Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2022 |
68968052508 |
CombiPatch Transdermal Patch Twice Weekly 0.05-0.25 MG/DAY - 8 each |
01/01/2022 |
11.02 |
231.49 |
None |
Single Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2022 |
68968555203 |
Daytrana Transdermal Patch 10 MG/9HR - 30 each |
01/01/2022 |
20.99 |
440.97 |
10/07/2025 |
Single Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2022 |
68968555303 |
Daytrana Transdermal Patch 15 MG/9HR - 30 each |
01/01/2022 |
20.99 |
440.97 |
10/07/2025 |
Single Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2022 |
68968555403 |
Daytrana Transdermal Patch 20 MG/9HR - 30 each |
01/01/2022 |
20.99 |
440.97 |
10/07/2025 |
Single Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2022 |
68968555503 |
Daytrana Transdermal Patch 30 MG/9HR - 30 each |
01/01/2022 |
20.99 |
440.97 |
10/07/2025 |
Single Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2022 |
68968662508 |
Minivelle Transdermal Patch Twice Weekly 0.025 MG/24HR - 8 each |
01/01/2022 |
10.43 |
219.13 |
07/04/2030 |
Innovator Multiple Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2022 |
68968663708 |
Minivelle Transdermal Patch Twice Weekly 0.0375 MG/24HR - 8 each |
01/01/2022 |
10.43 |
219.13 |
07/04/2030 |
Innovator Multiple Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2022 |
68968665008 |
Minivelle Transdermal Patch Twice Weekly 0.05 MG/24HR - 8 each |
01/01/2022 |
10.43 |
219.13 |
07/04/2030 |
Innovator Multiple Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2022 |
68968667508 |
Minivelle Transdermal Patch Twice Weekly 0.075 MG/24HR - 8 each |
01/01/2022 |
10.43 |
219.13 |
07/04/2030 |
Innovator Multiple Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2022 |
68968661008 |
Minivelle Transdermal Patch Twice Weekly 0.1 MG/24HR - 8 each |
01/01/2022 |
10.43 |
219.13 |
07/04/2030 |
Innovator Multiple Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000033 |
Novo |
03/31/2022 |
00169770521 |
Norditropin® FlexPro® 10mg/1.5mL |
01/06/2022 |
66.66 |
1465.40 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company. |
Rx0000033 |
Novo |
03/31/2022 |
00169770821 |
Norditropin® FlexPro® 15mg/1.5mL |
01/06/2022 |
100.00 |
2198.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company. |
Rx0000033 |
Novo |
03/31/2022 |
00169770321 |
Norditropin® FlexPro® 30mg/3.0mL |
01/06/2022 |
199.99 |
4396.20 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company. |
Rx0000033 |
Novo |
03/31/2022 |
00169770421 |
Norditropin® FlexPro® 5mg/1.5mL |
01/06/2022 |
33.33 |
732.70 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company. |